India operations to offset challenges in US market for Torrent Pharma

A weak outlook for the US market and a muted March quarter performance led to the downward revision of earnings of Torrent Pharma in the current financial year. As a consequence of the revision, the stock slipped 3.3 per cent on Tuesday. The key pain point has been performance in the US, with revenues falling 24 per cent on a sequential basis.  Performance in the region that contributes about a fifth to overall sales was pegged back by the recall of hypertension drug Losartan, as well as closure of a US plant. The discontinuation of key contributors to the top line and modernisation.....
Key stories on are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.